For private (and now public) healthcare and biotech companies, 2018 was a great year to raise capital with 16 companies reaching unicorn status. So far, in 2019, three more companies have been added to the list. Health Catalyst, which went public in July, Lyell Therapeutics and Rakuten Medical all reached the $1 billion valuation mark. Some significant changes happened in 2019, with Auris Health getting bought by Johnson & Johnson for $3.4 billion in February 2019, marking the company's valuation at over $5 billion.